Wuxi Biologics (Cayman) Inc.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. carries a market capitalization of 129.96B, placing it among publicly traded companies globally. Its enterprise value stands at 122.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Wuxi Biologics (Cayman) Inc.'s next confirmed earnings release is scheduled for March 23, 2027.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. has 4.13B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Wuxi Biologics (Cayman) Inc.'s stock has gained approximately 26.35% over the past 52 weeks. The 50-day moving average sits at 50.48, while the 200-day moving average is 39.56.

As of December 31, 2025, Wuxi Biologics (Cayman) Inc. holds 17.51B in cash and equivalents against 3.45B in total debt, resulting in a net debt position of -9.09B. Total book value stands at 52.58B, with working capital of 22.07B providing operational flexibility.

Wuxi Biologics (Cayman) Inc.'s most recent stock split took place on November 30, 2020 with a 1:3 split ratio.